Expression of Bcl-X(L), an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 577-583

  Torzewski, Michael ^a   Sarbia, Mario ^a   Heep, Hansjörg ^a   Dutkowski, Philipp ^b   Willers, Reinhart ^a   Gabbert, Helmut E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; ESOPHAGUS CARCINOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA;

EID: 0031946722     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Majno, G., and Joris, I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am. J. Pathol., 146: 3-15, 1995.
2. Rao, L., and White, E. Bcl-2 and the ICE family of apoptotic regulators: making a connection. Curr. Opin. Genet. Dev., 6: 39-44, 1997.
3. Yin, X. M., Oltvai, Z. N., and Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerisation with Bax. Nature (Lond.), 369: 321-323, 1994.
4. Zha, H., Aime-Sempe, C., Sato, T., and Reed, J. C. Pro-apoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizcs with Bax via a novel domain (BH3) distinct from BH1 and BH2. J. Biol. Chem., 271: 7440-7444, 1996.
5. Isaacs, J. T. Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer. Curr. Opin. Oncol., 6: 82-89, 1994.
6. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aimé-Sempé, C., Bofrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
7. Bronner, M. P., Culin, C., Reed, J. C., and Furth, E. E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am. J. Pathol., 146: 20-26, 1995.
8. L promotes susceptibility to mutagenesis. Oncogene, 13: 1489-1497, 1996.
9. Sarbia, M., Bittinger, F., Forschen, R., Verreet, P., Dutkowski, P., Willers, R., and Gabbert, H. E. bcl-2 expression and prognosis in squamous cell carcinomas of the esophagus. Int. J. Cancer, 69: 324-328, 1996.
10. Sarbia, M., Bittinger, F., Grabellus, F., Verreet, P., Dutkowski, P., Willers, R., and Gabbert, H. E. Expression of bax, a proapoptotic member of the bcl-2 family, in esophageal squamous cell carcinoma. Int. J. Cancer, 73: 508-513, 1997.
11. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-609, 1993.
12. Krajewski, S., Krajewska, M., Shabaik. A., Wang, H. G., Irie, S., Fong, L., and Reed, J. C. Immunohistochemical analysis of in vivo patterns of Bc1-X expression. Cancer Res., 54: 5501-5507, 1994.
13. International Union Against Cancer. TNM Classification of Malignant Tumours, 5th ed. New York: Wiley-Liss, Inc., 1997.
14. WHO. Histological Typing of Oesphageal and Gastric Tumours, 2nd ed. Berlin: Springer, 1990.
15. Suckow, E. E., Yokoo, H., and Brock, D. R. Intra-epithelial carcinoma concomitant with esophageal carcinoma. Cancer (Phila.), 15: 733-740, 1962.
16. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
17. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, box, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1576, 1996.
18. Krajewska, M., Fenoglio-Preiser, C. M., Krajewski, S., Song, K., Macdonald, J. S., Stemmermann, G., and Reed, J. C. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol., 149: 1449-1457, 1996.
19. L and Bcl-2 repress a common pathway of cell death. J. Exp. Med., 182: 821-828, 1995.
20. Krajewska, M., Moss, S. F., Krajewski, S., Song, K., Holt, P. R., and Reed, J. C. Elevated expression of bcl-X and reduced bak in primary colorectal adenocarcinoma. Cancer Res., 56: 2422-2427, 1996.
21. Gonzalez-Garcia, M., Perez-Ballestero, R., Ding, L., Duan, L., Boise, L. H., Thompson, C. B., and Nunez, G. bcl-XL is the major bcl-X mRNA form expressed during murine development and its product localizes to mitochondria. Development (Camb.), 120: 3033-3042, 1994.
22. Pezella, F., Turley, H., Kuzu, I., Tungekar, M. H., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. bcl-2 protein in non-small cell lung carcinoma. N. Engl. J. Med., 329: 690-694, 1993.
23. Öfner, D., Riehemann, K., Maier, H., Riedmann, B., Nehoda, H., Tötsch, M., Böcker, M., Jasani, B., and Schmid, K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer, 72: 981-985, 1995.
24. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzeti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
25. Joensuu, H., Pylkanen, L., and Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.
26. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ., 6: 363-370, 1995.
27. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res., 57: 62-67, 1997.
28. Kuhl, J. S., Krajewski, S., Duran, G. E., Reed, J. C., and Sikic, B. I. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. Br. J. Cancer, 75: 268-274, 1997.
29. L can differentially block chemotherapy-induced cell death. Blood, 90: 1208-1216, 1997.